On a DART-disclosed basis, revenue rose from KRW 42.3 billion in 2022 to KRW 81 billion in 2023, a 91.5% increase, then grew to KRW 89.2 billion in 2024 (up 10.2%) and KRW 95.9 billion in 2025 (up 7.5%), marking three consecutive years of growth.
Operating results swung from an operating loss of KRW 10.1 billion in 2022 to operating profit of KRW 6.05 billion in 2023, then rose to KRW 10.7 billion in 2024 (up 77.1%). Operating profit fell 84.8% in 2025 to KRW 1.63 billion, and the operating margin declined from 12.0% to 1.7%.
Shareholder net profit peaked at KRW 25.7 billion in 2023 and then declined two years in a row, to KRW 13.3 billion in 2024 (down 48.2%) and KRW 2.84 billion in 2025 (down 78.7%). Net profit including non-controlling interests was KRW 2.05 billion in 2025, a different figure from shareholder net profit.
According to an analysis by Cosmetic Shinmun, the gross margin fell from 46.8% to 41.1% in 2025, and R&D expenses rose 89.8% to KRW 5.1 billion.
The same analysis said profitability at domestic and overseas subsidiaries worsened, and the domestic subsidiary KBTB, a consolidated subsidiary, posted a net loss of KRW 3.9 billion in 2025.
Quarterly results show operating losses of KRW 2.36 billion in Q4 2025, KRW 1.48 billion in Q1 2026 and KRW 366 million in Q2 2026, before an operating profit of KRW 3.24 billion in Q3 2026.
On November 16, 2026, the company said standalone Q3 operating profit was KRW 4 billion with a 17.6% margin, a preliminary figure. The cumulative shareholder net loss over the last four quarters is KRW 4.18 billion.